News
Best Pharma Shredder Manufacturer
We have a very wide range of pharma shredders developed over the years from practical shredding experience, these machines are manufactured in standard as well as GMP versions, The machines are carefully manufactured in our factory in Mumbai ,...
News
How Oral Semaglutide Extends GLP-1 Delivery Into Weight Management
The development of oral semaglutide (for example, oral Wegovy) for weight management matters because it addresses a problem that goes well beyond patient convenience. Injectable incretin therapies, including semaglutide and tirzepatide pens, have dominated the
weight-management category in recent years,...
Business & Industry
Sigma Healthcare Pursues Potential Boots Acquisition Deal
Australia’s Sigma Healthcare has confirmed that it is participating in discussions regarding a possible acquisition of Boots, the UK health and beauty retailer, in a transaction reportedly valued at up to $10 billion. The company acknowledged its interest after...
Business & Industry
MHRA Launches AI Sandbox to Accelerate Drug Development
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the launch of a new AI Sandbox programme designed to explore how artificial intelligence can strengthen medicines safety, improve risk prediction and support faster development of new treatments. Announced...
Business & Industry
Pfizer’s Hympavzi Wins FDA Expanded Approval for Haemophilia A and B
Pfizer has secured an expanded indication approval from the US Food and Drug Administration (FDA) for Hympavzi (marstacimab-hncq), broadening its use in the treatment of haemophilia A or B. The updated approval extends coverage to patients aged 12 years...
Business & Industry
Incyte Expands Haematology Portfolio with Vega Acquisition
Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction valued at up to $2bn, reinforcing its presence in haematology with the addition of a late-stage treatment candidate for bleeding disorders. Under the terms...
Business & Industry
GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition
GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read